CRISPR Therapeutics AG (CRSP) Return on Capital Employed (2016 - 2026)
CRISPR Therapeutics AG (CRSP) posted Return on Capital Employed of 27.4% for Q1 2026, up 13.17% sequentially from 31.55% in Q4 2025, and down 464.0% YoY from 7.53% in Q1 2025.
CRISPR Therapeutics AG (CRSP) Return on Capital Employed (2016 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported Return on Capital Employed for 11 years, with the latest figure at 27.4% in Q1 2026.
- Quarterly Return on Capital Employed fell 464.0% year-over-year to 27.4% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 27.4% (down 464.0% YoY) and the FY2025 annual result came in at 31.58%, down 986.0% from the prior year.
- Return on Capital Employed improved to 27.4% in Q1 2026 per CRSP's latest filing, from 31.55% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 12.17% in Q1 2022 and troughed at 31.55% in Q4 2025.
- A 5-year average of 21.2% and a median of 22.76% in 2025 frame the typical range for Return on Capital Employed.
- The widest YoY moves for Return on Capital Employed: up 3401 bps in 2022, down 4548 bps in 2022.
- Over 5 years, Return on Capital Employed stood at 30.92% in 2022, then soared by 65 bps to 10.86% in 2023, then slumped by 99 bps to 21.59% in 2024, then slumped by 46 bps to 31.55% in 2025, then grew by 13 bps to 27.4% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 27.4%, 31.55%, and 28.46% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | -20.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20.91% |
| Mar 31, 2026 | -27.40% |
| Dec 31, 2025 | -31.55% |
| Sep 30, 2025 | -28.46% |
| Jun 30, 2025 | -27.71% |
| Mar 31, 2025 | -22.76% |
| Dec 31, 2024 | -21.59% |
| Sep 30, 2024 | -15.05% |
| Jun 30, 2024 | -15.68% |
| Mar 31, 2024 | -13.48% |
| Dec 31, 2023 | -10.86% |
| Sep 30, 2023 | -20.86% |
| Jun 30, 2023 | -22.69% |
| Mar 31, 2023 | -26.79% |
| Dec 31, 2022 | -30.92% |
| Sep 30, 2022 | -30.45% |
| Jun 30, 2022 | -26.25% |
| Mar 31, 2022 | 12.17% |
| Dec 31, 2021 | 14.01% |
| Sep 30, 2021 | 14.88% |